These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26104996)

  • 41. Fungal carriage on healthcare workers' hands, clothing, stethoscopes and electronic devices during routine patient care: a study from a tertiary care center.
    Keri VC; Kumar A; Singh G; Xess I; Khan MA; Rastogi N; Sahu M; Wig N
    J Prev Med Hyg; 2021 Mar; 62(1):E170-E173. PubMed ID: 34322633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Microbial contamination of domiciliary nebuliser therapy equipment.
    Jones PD; Moritz V; Pierce RJ
    Aust N Z J Med; 1985 Oct; 15(5):585-9. PubMed ID: 3867335
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nebuliser systems for drug delivery in cystic fibrosis.
    Daniels T
    J Evid Based Med; 2013 Aug; 6(3):201. PubMed ID: 24325379
    [No Abstract]   [Full Text] [Related]  

  • 44. Inhaled interventions in cystic fibrosis: mucoactive and antibiotic therapies.
    Hurt K; Bilton D
    Respiration; 2014; 88(6):441-8. PubMed ID: 25472021
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of nebuliser therapy in cystic fibrosis.
    Geddes D
    Prof Care Mother Child; 1995; 5(6):147, 149. PubMed ID: 8680235
    [No Abstract]   [Full Text] [Related]  

  • 46. Microbial contamination of liposomal amphotericin B nebuliser devices in lung transplant patients.
    Fernández-Huerta M; Escobar R; Monforte V; Rodriguez V
    Enferm Infecc Microbiol Clin (Engl Ed); 2019 Mar; 37(3):211-212. PubMed ID: 29754979
    [No Abstract]   [Full Text] [Related]  

  • 47. Cleaning and infection control of airway clearance devices used by CF patients.
    Manor E; Gur M; Geffen Y; Bentur L
    Chron Respir Dis; 2017 Nov; 14(4):370-376. PubMed ID: 28513198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aerosol antibiotic treatment in cystic fibrosis.
    Littlewood JM; Smye SW; Cunliffe H
    Arch Dis Child; 1993 Jun; 68(6):788-92. PubMed ID: 8333776
    [No Abstract]   [Full Text] [Related]  

  • 49. A widely available method for the assessment of aerosol delivery in cystic fibrosis.
    Kastelik JA; Wright GA; Aziz I; Davies M; Avery GR; Paddon AJ; Howey S; Morice AH
    Pulm Pharmacol Ther; 2002; 15(6):513-9. PubMed ID: 12493338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct isotopic assessment of aerosolized pentamidine deposition: influence of nebuliser.
    Diot P; Le Pape A; Becquemin MH; Besnier JM; Boissinot E; Bastides F; Benjemaa M; Choutet P; Lemarie E
    Eur J Med; 1993; 2(8):484-8. PubMed ID: 8258049
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis.
    Guy EL; Bosomworth M; Denton M; Conway SP; Brownlee KG; Lee TW
    J Cyst Fibros; 2010 Jul; 9(4):292-5. PubMed ID: 20427245
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bacterial contamination of spacer devices used by asthmatic children.
    Cohen HA; Cohen Z; Pomeranz AS; Czitron B; Kahan E
    J Asthma; 2005 Apr; 42(3):169-72. PubMed ID: 15962872
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does repeated disinfection of the e-Flow rapid nebulizer affect in vitro performance?
    Bakuridze L; Andrieu V; Dupont C; Dubus JC
    J Cyst Fibros; 2007 Jul; 6(4):309-10. PubMed ID: 17276148
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis.
    McCormack P; McNamara PS; Southern KW
    J Cyst Fibros; 2011 Sep; 10(5):343-9. PubMed ID: 21620782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Device Cleaning and Infection Control in Aerosol Therapy.
    O'Malley CA
    Respir Care; 2015 Jun; 60(6):917-27; discussion 928-30. PubMed ID: 26070583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nebuliser cleaning and disinfection practice in the home among patients with cystic fibrosis.
    MacFarlane M; Carson L; Crossan A; Bell J; Moore JE; Millar BC
    J Infect Prev; 2020 Jan; 21(1):14-22. PubMed ID: 32030099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Other medications for aerosol delivery.
    Rubin BK
    Paediatr Respir Rev; 2006; 7 Suppl 1():S76-9. PubMed ID: 16798603
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cleaning of inpatient nebulizer devices in cystic fibrosis patients: the urgent need for universal guidelines.
    Bell J; Moore JE; Millar BC
    J Hosp Infect; 2018 Nov; 100(3):e64-e66. PubMed ID: 30369424
    [No Abstract]   [Full Text] [Related]  

  • 59. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of suspension particle size on the performance of air-jet, ultrasonic and vibrating-mesh nebulisers.
    Najlah M; Parveen I; Alhnan MA; Ahmed W; Faheem A; Phoenix DA; Taylor KM; Elhissi A
    Int J Pharm; 2014 Jan; 461(1-2):234-41. PubMed ID: 24275450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.